Pradip Raychaudhuri, PhD Professor of Biochemistry & Molecular Genetics University of Illinois, Chicago Chicago, Il-60607, USA My lab has been studying the proliferation-associated transcription factor FoxM1 whose over-expression strongly correlates with aggressive tumor progression. We showed that FoxM1 is critical for liver tumor development and progression (Genes & Dev., 2004). Also, our functional studies demonstrated that FoxM1 is required for the survival of liver tumor cells expressing ROS-inducing oncogenes, such as activated Ras and Akt (EMBO J. 2009). FoxM1 is the major regulator of ROS in aggressive cancers. It supports survival of the cancer cells by regulating the levels of ROS through transcriptional induction of the antioxidant genes. We showed that in breast cancer cells over-expressed FoxM1 confers resistance to herceptin and taxol (Cancer Res. 2010). In addition, we demonstrated that expression of FoxM1 drives metastasis of liver tumors. We observed evidence that FoxM1b is a master activator of tumor metastasis in liver cancer model (EMBO Molecular Medicine, 2011, Cancer Res. 2011). Also, recently, we showed that targeting FoxM1 after tumor development causes inhibition of progression (J. Hepat. 2015). We showed that FoxM1 inhibits Rb to support liver tumor progression (Oncogene, 2022). Currently, the lab focusses on a gene-silencing function of FoxM1 with regards to its role in liver cancer development. Over 100 peer reviewed publications. H-index: 56. Editorial board (2019-present): Cancers; Membership: AACR. Contributions to Science: (1) Discovered RB/E2F interactions, which is now the foundation of our understanding of the mechanisms that regulate the cell cycle. (2) Discovered the Cul4/DDB interactions and their roles as an E3 Ubiquitin ligase. (3) Discovered critical roles of FoxM1 in liver cancer development and progression. (4) Demonstrated that inhibition of FoxM1 inhibits liver cancer progression. (5) Discovered that FoxM1 functions as a transcriptional repressor by binding to RB and DNMT3b. (6) Discovered that the repression function of FoxM1 is critical for liver cancer progression. I served in the editorial board of Hepatology for 2 years (2006-2008). Currently, in the editorial board of Cancers. Other than that, I serve as ad hoc reviewer for many journals, including Science, Nature journals, Cell, Cell Reports and many others. I have a strong interest in liver cancer with regards to mechanisms of development and progression. Currently, research in my lab focuses on the fatty liver diseases (MASLD) as they are related to liver cancer development. Areas of expertise: Oncological sciences, Cell biology, Molecular Genetics. I have been running an active research program (continuously funded) for over 30 years that requires all the skills that are listed. Astrophysics and Philosophy.